Skip to main content
Ying Liu, MD, Oncology, New York, NY

YingLiuMDMPH

Oncology New York, NY

Gynecologic Cancer

Assistant Attending, Memorial Sloan Kettering Cancer Center

Overview of Dr. Liu

I am a board certified, academic medical oncologist focused on GYN cancers and inherited cancer syndromes/cancer genetics.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2020
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterOncology, 2020
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2013 - 2016
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2013
  • University of North Carolina School of Public Health
    University of North Carolina School of Public HealthMPH, 2011 - 2012
  • University of North Carolina at Chapel Hill
    University of North Carolina at Chapel HillBS, Chemistry - Biochemistry, 2005 - 2009
  • University of North Carolina at Chapel Hill
    University of North Carolina at Chapel HillBS, Chemistry � Biochemistry track, 2005 - 2009

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • CT State Medical License
    CT State Medical License 2023 - 2025
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • NY State Medical License
    NY State Medical License 2014 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • ASCO CCF Young Investigator's Award
  • Young Investigator Award ASCO CCF, 2019
  • Clinical Scholar Award SABCS, 2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Psychosocial comorbidities are differentially associated with subclinical atherosclerosis in rheumatoid arthritis: Comparison with MESA  
    Liu YL, Szklo M, Davidson KW, Bathon JM, and Giles JT, Arthritis Care & Research., 1/1/2015

Abstracts/Posters

  • Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
    Liu Y, American Society of Clinical Oncology Annual Meeting, 1/1/2019
  • Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer.
    Liu Y, American Society of Clinical Oncology Annual Meeting, 1/1/2019
  • Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer
    Liu Y, Society of Gynecological Oncology (SGO) AnnualMeeting, 1/1/2019
  • Join now to see all

Lectures

  • Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression durin... 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
  • Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Alpha‐Actinin‐4 Is Essential for Maintaining Normal Trophoblast Proliferation and Differentiation During Early Pregnancy
    Alpha‐Actinin‐4 Is Essential for Maintaining Normal Trophoblast Proliferation and Differentiation During Early PregnancyMarch 23rd, 2021
  • Functional Oral Nanoparticles for Delivering Silibinin and Cryptotanshinone Against Breast Cancer Lung Metastasis
    Functional Oral Nanoparticles for Delivering Silibinin and Cryptotanshinone Against Breast Cancer Lung MetastasisMay 30th, 2020
  • Toripalimab plus Chemo Dubbed New Standard First-Line Therapy for ES-SCLC
    Toripalimab plus Chemo Dubbed New Standard First-Line Therapy for ES-SCLCOctober 31st, 2023

Professional Memberships

Other Languages

  • Chinese (Mandarin), Spanish